TrialSignal transduction and targeted therapy2026

HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial).

Huai-Liang Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.